Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 13;21:54. doi: 10.1186/s12964-023-01076-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — EIF5A2 overexpression in LUAD is associated with poor survival. A Genomic alterations of EIF5A1 and EIF5A2 analysis using the dataset of TCGA Pan-Cancer Atlas Studies at the cBioPortal for Cancer Genomics. Green, mutation; red, amplification; blue, deep deletion. B Survival prognostic curve in patients with LUAD is shown. C eIF-5A2 localises in the nucleus, perinucleus and cytoplasm of cancer cells. In normal lung tissues eIF-5A2 is expressed in alveolar walls and cytoplasm of alveolar macrophages. Tissue microarray immunohistochemistry of the samples from patients LF01, LF05, LF09, LF15, LF19, LF20, LF21 and LF29 [35]. Normal lung tissue adyacent to primary tumor and primary tumor tissue are shown. Images show Hematoxylin and eosin (H&E) staining along immunohistochemistry with the anti-eIF-5A2 antibody. Sale bar for 5X images are 500 µm; scale bar for 20X images are 100 µm